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Noonan Syndrome (NS) is an autosomal dominant multisystem disorder,
characterised by short stature, distinctive facial dysmorphism, cardiovascular
abnormalities and developmental delay. Its estimated incidence is 1:1000 to 1:2500
live births. NS is caused by germline mutationsin more than ten genes encoding
proteins integral to the Ras/MAPK signaling pathway. Pathogenic variants in these
genes account for 70-80% of NS cases. The clinical diagnosis of NS can be
challenging in some cases, even when performed by experienced clinicians. The
introduction of Next Generation Sequencing (NGS) technology in clinical practice in
the Western world has tremendously facilitated the molecular diagnosis of
RASopathies. Molecular testing for NS is not yet available in South Africa, nor has
any study investigating NS from clinical and molecular perspectives been conducted
in South Africans.
Aim
The aim of this study was to investigate selected genes within a group of paediatric
and adult patients with a clinical diagnosis of NS.
Methods
This study was a cross-sectional descriptive study, including twenty-six familial and
isolated NS patients recruited in Cape Town in the period January 2015-January
2017. Thorough phenotyping of each patient according to the international diagnostic
criteria for NS was followed by targeted NGS, performed on leucocyte DNA samples
from sixteen unrelated patients out of the twenty-six included. Sequencing involved
all the exons and intron-exon boundaries of a predesigned panel of 14 genes,
including A2ML1, BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11,
RAF1, RIT1, SHOC2, SOS1 and SPRED1.
Results
Of the 26 patients included, 50% had a family history suggestive of NS.The median
age at diagnosis was4.5 years (range: 1month-51years). Individuals of mixed-race
ancestry were most represented (53.8%), followed by black Africans (30.8%). The
clinical features identified were consistent with those reported in other populations.
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Compared to other series, our cohort revealed a lower frequency of Pulmonary Valve
Stenosis (34.6%) and a less severe developmental phenotype.
Variants predicted pathogenic were detected in 7(43.7%) DNA samples out of the 16
analysed. The genes involved were CBL in three cases (42.8%), PTPN11and
MAP2K1in two cases (28.6%, for each gene). Surprisingly,the proportion of CBL
variants was relatively high compared to those in the literature. Genotype-phenotype
correlations showed that clinical features of NS were more typical in patients with
pathogenic variants in MAP2K1, and less in those with variants in CBL.
Conclusion
This is the first clinical and molecular study in South Africanswith the NS phenotype.
The phenotype of affected individuals with NS in South Africa is globally similar to
that reported in the literature. Therefore, the use of international diagnostic criteria
can effectively enable the clinical diagnosis of NS in most South African patients.
These preliminary data suggest that the distribution of pathogenic variants in NS
genes in South Africans may be different from that reported in other populations.
Finally, this study demonstrates that Targeted NGS can be successfully applied to
the molecular diagnosis of NS and related conditions in South Africa, and should be
implemented in clinical practice.
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW
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1.1 THE RASOPATHIES
The RASopathies are a well-defined group of clinically and genetically related
developmental disorders, caused by germline pathogenic variants in genes playing a
role in the Ras/Mitogen-Activated Protein Kinase (MAPK) signalling pathway
(Tidyman & Rauen 2009). This well-studied signal transduction pathway is critical for
normal mammalian development, with the control of several vital cellular functions
including cell cycle, cell growth, differentiation and survival (Yoon & Seger 2006;
Rauen 2013). While each RASopathy has a distinctive phenotype, RASopathies
share several clinical characteristics because of their similar effect on the
dysregulation of the Ras/MAPK pathway. This group of genetic disorders includes:
Neurofibromatosis Type 1 (NF-1), Noonan Syndrome (NS), Costello Syndrome (CS),
Cardiofaciocutaneous Syndrome (CFC), Noonan Syndrome with multiple lentigines
previously known as LEOPARD syndrome (NSML), Legius Syndrome (LS) and
Capillary Malformation-Arteriovenous Malformation Syndrome (CM-AVM) (Figure 1).
Figure 1: The Ras/MAPK signaling pathway (Adapted fromAoki et al. 2016).
This figure illustrates the relationship between known RASopathies and their associated




Noonan Syndrome (NS) is likely the second most common RASopathy after
Neurofibromatosis Type 1, with an estimated incidence of 1:1000 to 1:2500 live
births (Mendez  & Opitz 1985). It is caused by germline mutations in several genes
known as either components or regulators of the Ras/MAPK signalling pathway
(Tidyman & Rauen 2009). NS is transmitted following autosomal dominant pattern of
inheritance owing to family clustering, with 30-75% of patients having an affected
parent (Allanson & Roberts 2001).
1.2.1 CLINICAL PRESENTATION
Individuals affected by NS present with multisystem involvement, including short
stature, distinctive facial dysmorphism and a wide range of cardiovascular and other
abnormalities (Figure 2 and Tables 1, 2&3). It is believed that many physical features
of NS are caused by lymphatic dysfunction or obstruction during development
(Allanson 2007).
Figure 2: Child/adolescent and adult with Noonan Syndrome (adapted from Bhambhani
& Muenke 2014). This figure provides a graphic representation of the dysmorphic features
found in NS.
The condition is clinically heterogeneous with variable expressivity, even within the
same affected family. Some physical features associated with NS, especially the
facial dysmorphism, alter with age and can considerably vary among different age
groups (Allanson et al. 1985; Roberts et al. 2013).
     
      
       
     
    
     
    
      
      
   
   
    
  
    
     
  
 














Table 1: Typical facial features of NS by age group (Adapted fromRoberts et al. 2013)
and Romano et al. 2010)
The table below presents and compares the facial features of NS in four age groups.
Forehead,
face, hair
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Adolescence
(12-18 years)























Table 2: Cardiovascular features of NS
Congenital heart diseases (CHDs) are present in 50-80% of individuals with NS. The
most common is Pulmonary Valve Stenosis, usually with a dysplastic valve. In NS,
Hypertrophic Cardiomyopathy (HCM) can occur in the prenatal or postnatal period.








Others less common (Aortic
coarctation, mitral valve







2013; Prendiville et al.
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(90) (Sharland et al. 1992;
Raaijmakers et al. 2008)
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Table 3: Other clinical features in NS
This table provides a summary of the clinical manifestations of NS reported in clinical studies











o Pectus carinatum superiorly
o Pectus excavatum inferiorly
Spine
o Scoliosis
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o Poor suck with prolonged
feeding time
o Very poor suck and slow
feeding with recurrent
vomiting
o Severe feeding problems








(Romano et al. 2010;
Sharland et al. 1992)
Genitourinary Undescended testes
Renal abnormalities
Sertoli cell dysfunction in males
60 - 80
10-11
(Sharland et al. 1992;











(KUMAR et al. 2014;
Neumann et al. 2009)
Auditory
Sensorineural hearing loss


















(Van der Burgt 2007;




o Sitting alone: 10 months
o Walking: 21 months
Speech delay
o Speaking 2-word sentences:
31-32 months







(Witt et al. 1987;
Romano et al. 2010)
Dermatology
Pigmented naevi
Café au lait spots








(Sharland et al. 1992)
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1.2.2 MOLECULAR GENETICS
At the molecular level, NS is highly heterogeneous with heterozygous germline
pathogenic variants reported in more than ten genes (Aoki et al. 2016), all of them
encoding proteins which are components or regulators of the Ras/MAPK signalling
pathway. NS-causing genes include genes that encode proteins of the Ras family of
GTPases (KRAS, NRAS, RIT1, and RRAS), modulators of Ras function (PTPN11,
SOS1, SOS2, A2ML1, CBL, RASA2, and SHOC2) and downstream signal
transducers (RAF1, BRAF and MEK1or MAP2K1) (Tartaglia et al. 2001;Roberts et
al. 2007; Aoki et al. 2013;Flex et al. 2014;Vissers et al. 2015; Yamamoto et al. 2015;
Cordeddu et al. 2015). Mutations associated with NS in these genes result in gain-of-
function within the Ras/MAPK signalling pathway, and account for approximately
80% of all NS cases (Cordeddu et al. 2015). Missense mutations in PTPN11 alone
are found in about 50% of affected individuals (Tartaglia & Gelb 2005), while SOS1
has been reported to be the second most mutated gene, accounting for 10-20% of
PTPN11-negative patients (Roberts et al. 2007).
1.2.3 CLINICAL AND MOLECULAR DIAGNOSIS
1.2.3.1 CLINICAL DIAGNOSIS
The clinical diagnosis of NS is made through recognition of a combination of key
physical features and cardiovascular abnormalities, with or without a positive family
history (Romano et al. 2010). A number of clinical scoring systems have been
proposed to assist in the diagnostic process of NS, including a comprehensive
diagnostic scoring system combining minor and major features established by Van
der Burgt and collaborators in 1994(Table 4) (Van der Burgt 2007). The clinical
diagnosis of NS can be more difficult in adulthood, as many adults present with
subtle clinical features. Most adults are diagnosed for the first time after the birth of
an affected child (Shaw et al. 2007). Furthermore, overlapping features with other
RASopathies, especially Cardiofaciocutaneous Syndrome and Costello Syndrome,
can make the clinical diagnosis of NS very challenging in some cases.
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Table 4: Diagnostic scoring system for NS(Van der Burgt 2007)
This table provides the diagnostic scoring system for NS elaborated by Van der
Burgt in 1994.
Definitive NS: Criterion 1A + one of 2A-6A or 1A + two of 2B-6B
Criterion 1B + two of 2A-6A or 1B + three of 2B-6B
Feature A = Major B = Minor
1 Facial Typical face dysmorphology
(Allanson. 1987)
Suggestive face dysmorphology
2 Cardiac Pulmonary valve stenosis, HCM
and/or ECG typical of NS
Other defects
3 Height <3 centile <10 centile
4 Chest wall Pectus carinatum/excavatum Broad thorax
5 Family
history
First degree relative with definite NS First degree relative with
suggestive NS
6 Other Developmental delay, cryptorchidism
and lymphatic dysplasia




The molecular diagnosis of NS involves the testing of specific genes known to be
associated with the disorder. Different testing approaches can be used in clinical
settings:
a. Single gene analysis
This approach involves the use of Sanger sequencing to test for specific variants in a
selected gene (Tartaglia et al. 2001). This traditional method has been extensively
used for the molecular diagnosis of NS, and remains the gold-standard DNA
sequencing technique for confirmation of sequence variants(Tartaglia et al. 2001;
Roberts et al. 2007). Due to high genetic heterogeneity, the typical diagnostic testing
protocol for NS requires a multi-step approach, using PCR and Sanger sequencing.
The selection of which gene or genes to investigate as a first diagnostic step is
based on the frequency of association with the condition and the relationship with a
particular phenotype (Lepri et al. 2014). The downside of using Sanger sequencing
is that only one PCR fragment can be sequenced at a time, making this method
laborious, time consuming and expensive.
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b. Multigene analysis
This approach involves the use of massively parallel sequencing (MPS), also known
as next generation sequencing (NGS), which allows for the simultaneous testing of
multiple genes (Teer & Mullikin 2010). In clinical settings, this can be achieved using
at least two methods:
 Whole exome sequencing
Whole exome sequencing (WES) covers the entire protein-coding region of the
genome and as such, is capable of detecting known disease-causing variants as well
as new mutations leading to the discovery of novel gene–disease associations.
While highly effective, WES presents a number of difficulties in a clinical setting,
mostly relating to the challenges of high throughput data analysis, the interpretation
and validation of findings, and the possibility of incidental findings(Rehm et al.
2013).Furthermore, the  non-uniformity of the depth of coverage for an exome may
lower its  analytical sensitivity, which may  result in a lack of sufficient coverage in
genes/regions of interest (Rehm et al. 2013).
 Disease-targeted gene panel
This method is used to investigate well-known disease-associated genes. Targeted
gene sequencing allows for the testing of specific genes of interest at the same time,
as opposed to the whole genome or exome (Rehm et al. 2013). This targeted
approach allows greater depth of coverage, with higher analytical sensitivity and
specificity than WES. Moreover, because only well-known disease-associated genes
are sequenced, data analysis and interpretation in a clinical context are less
complex. Targeting fewer genes also allows for a higher sample throughput in a
clinical laboratory, compared to WES (Rehm et al. 2013). A disease-targeted gene
panel is currently seen as the most effective  approach in a clinical setting, and has
been efficiently used for the molecular diagnosis of NS (Lepri et al. 2014).
1.2.4 MANAGEMENT
Comprehensive management guidelines for NS have been developed by several
consortia, including an American consortium (Romano et al. 2010), a European
consortium (Noonan Syndrome Guideline Development Group 2010) and other
authors (Allanson 2007;Roberts et al. 2013).
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1.2.4.1 EVALUATION FOLLOWING INITIAL DIAGNOSIS
The following evaluations are recommended in newly diagnosed individuals with NS:
 General: complete clinical and neurological examination, medical genetics
consultation, molecular genetic testing and eventually, genetic counselling
 Growth and feeding: plotting of growth parameters on NS special growth
charts
 Development: developmental evaluation by a multidisciplinary team
 Cardiovascular: cardiovascular examination by a cardiologist,
electrocardiogram (ECG) and echocardiogram
 Haematological: coagulation screen including complete blood count with
differential, prothrombin time (PT) or activated partial prothromboplastin time
(aPTT)
 Dental: dental assessment between 1-2 years of age
 Audiology: baseline hearing assessment
 Ophthalmology: baseline ophthalmologic examination
 Kidney: baseline renal ultrasound
 Skeletal: clinical assessment of spine and rib cage with radiography, if
indicated
1.2.4.2 LONG TERM FOLLOW-UP
The long term follow-up plan recommended in affected individuals is as follows:
 General: yearly complete clinical and neurological examination; return to
medical geneticist if negative genotype; genetic counselling when
adolescent or young adult
 Growth and feeding: plotting of growth parameters on NS special growth
charts three times per year until 3 years old and yearly thereafter
 Development: developmental assessment yearly for children aged 5-18
years
 Cardiovascular: follow-up based on initial findings; if the heart is normal
initially, repeat assessment every 5 years. Adults should not discontinue
their cardiac evaluations even if initially normal in childhood or
adolescence
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 Haematological: repeat coagulation screen including complete blood
count with differential, PT/aPTT after 6-12 months if the initial screen was
done in infancy; pre-operatively, perform coagulation screen including
complete blood count with differential, PT/aPTT and in consultation with
haematologist: factor IX, XI, and XII concentrations, Von Willebrand factor,
platelet function (bleeding time or platelet aggregation)
 Audiology: repeat hearing assessment if there is recurrent otitis or
speech delay
 Ophthalmology: repeat ophthalmologic examination every two years or
appropriately if initial evaluation is abnormal
 Dental: dental assessment between 1-2 years of age and yearly
examination thereafter
 Others: for other organ-systems, follow-up or referral as indicated,
depending on the initial evaluation.
1.2.4.3 TREATMENT OF MANIFESTATIONS
The treatment of NS-associated complications does not generally differ from
standard treatments in the general population. Aspirin therapy should be avoided in
affected individuals with a bleeding diathesis. (Allanson 2007; Noonan Syndrome
Guideline Development Group 2010; Romano et al. 2010; Roberts et al. 2013).
1.2.5 GENETIC COUNSELLING
NS is inherited in an autosomal dominant fashion (Sharland et al. 1992).
1.2.5.1 RISK TO FAMILY MEMBERS
 Parents: approximately 30-75% of individuals newly diagnosed with NS have
an affected parent (Allanson & Roberts 2001). In the remaining cases, the
condition results from a de novo pathogenic variant. Thorough assessment of
apparently healthy parents of a newly diagnosed child is recommended
(Allanson & Roberts 2001).
25
 Siblings: the risk to the siblings depends on the genetic status of the parents.
The risk to the siblings is 50% if one of the parents has the pathogenic variant
identified in the proband. If the pathogenic variants identified in the proband
are not detected in the leucocytes DNA of otherwise healthy parents, the risk
to the siblings is low (<1%), but greater than that of the general population
because of the possibility of germline mosaicism (Yoon et al. 2013).
 Offspring: the risk to each child of an affected individual with NS is 50%.
 Other family members: the risk to other family members depends on the
status of the parents. They may be at risk if a proband’s parent is affected.
1.2.5.2 PRENATAL AND PREIMPLANTATION GENETIC DIAGNOSIS
Prenatal genetic diagnosis for pregnancies at increased risk for NS and
preimplantation genetic diagnosis can be offered to families with a known pathogenic
variant previously identified in an affected family member (Roberts et al. 2013).
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1.3 RATIONALE OF THE STUDY
With an incidence of 1 in 1000-2500 live births, NS is a common genetic condition
worldwide (Mendez HM 1985). Affected individuals can have a relatively normal
lifespan, subject to an early molecular diagnosis and appropriate long term follow-up
(Noonan Syndrome Guideline Development Group 2010; Romano Alicia et al. 2010;
Roberts et al. 2013).
The clinical diagnosis of NS is straightforward in many cases, but overlapping clinical
characteristics with a number of RASopathies, as well as the subtle clinical
presentation in some age groups (such as newborns and adults) can make the
diagnosis problematic (Roberts et al. 2013; Lepri et al. 2014). Many familial and
sporadic paediatric and adult cases have been clinically identified in South Africa,
but to the best of our knowledge, molecular diagnosis is currently not available
locally. Determining the molecular diagnosis of our patients may not only allow
confirmation of our clinical findings, but may also facilitate timely family interventions
through cascade screening. Moreover, successful introduction of NGS technology in
clinical practice in the western world (Rehm et al. 2013; Lepri et al. 2014), as well as
efforts currently made by the South African health system to do the same, could
facilitate the establishmentof comprehensive gene panel testing for NS in the
country. To the best of our knowledge, no research investigating the genetic
aetiology of NS in South African patients has been previously conducted. The
present study aims to characterise a cohort of South African NS patients from a
clinical and genetic perspective. This would provide preliminary insights into the
mutation prevalence in local NS patients and possible specific genotype/phenotype
correlations and founder effects. The use of targeted gene panel NGS ultimately
aims at establishing a molecular diagnostic service for NS in South Africa.
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1.4 AIM AND OBJECTIVES OF THE STUDY
1.4.1 AIM
The aim of this study was to investigate selected genes within a group of paediatric
and adult patients with a clinical diagnosis of Noonan Syndrome.
1.4.2 OBJECTIVES
The objectives of this study were:
a. To identify, both retrospectively and prospectively, familial and sporadic cases
of NS;
b. To undertake a thorough phenotyping of each selected proband;
c. To perform molecular analysis on a genetic sample from each proband;







The present study is a cross-sectional and descriptive study.
2.2 PATIENT DESCRIPTION
2.2.1 ETHICAL APPROVAL
Ethical approval was granted by the Human Research Ethics Committee of the
University of Cape Town (HREC REF: 449/2016). All adult participants signed
consent forms, while informed consent was given by the parents of participants
younger than 18 years of age.
2.2.2 CHARACTERISTICS OF THE STUDY POPULATION
2.2.2.1 STUDY POPULATION
Consecutive patients attending paediatric  and adult genetic clinics at the Red Cross
War Memorial Children’s Hospital (RCWMCH) and  Groote Schuur Hospital (GSH)
respectively,between January 2015 and January 2017.
2.2.2.2 NUMBER OF PARTICIPANTS
Twenty six (n= 26) participants were selected using convenience sampling.
2.2.2.3 INCLUSION CRITERIA
 Adult and paediatric patients of both genders meeting the Van der Burgt
scoring system criteria for clinical diagnosis of NS
 Familial and simplex cases of NS
 Available for clinical examination, provision of informed consent for genetic
testing
2.2.2.4 EXCLUSION CRITERIA
 Patients not consenting to participate in the study
2.2.3 RECRUITMENT AND ENROLMENT
The recruitment was both retrospective and prospective. Retrospectively, known
families and individual patients from the clinical database of the Division of Human
Genetics, University of Cape Town (UCT) with a clinical diagnosis of NS were
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contacted by telephone and invited by the candidate, Dr Cedrik Ngongang, in his
capacity as genetic registrar, to attend special consultations aimed at obtaining
informed consent and data collection. Prospectively, every new patient meeting the
inclusion criteria and attending our paediatric or adult clinics during the recruitment
period was enrolled. Informed consent and data collection were done by the
candidate in the presence of the study supervisoratRCWMCH and GSH.
2.2.4 DATA COLLECTION METHODS
2.2.4.1 PATIENT SELECTION PROCEDURE
 Retrospectively and prospectively, probands were selected based on the
adopted diagnostic scoring system developed by Van der Burgt(Van der Burgt
2007). The clinical diagnosis of NS was made in the presence of typical facial
features plus an additional major feature or two minor features. In the
presence of suggestive facial features, patients had to have at least two major
features or three additional minor features. Major characteristics included
cardiac abnormalities (pulmonary valve stenosis, HCM and/or ECG typical of
NS), height below the 3rd centile, chest deformities (pectus
carinatum/excavatum),positive family history (first degree relative with definite
NS)and the following: undescended testes in male subjects, developmental
delayand lymphatic dysplasia. Minor characteristics included any other
cardiac defects, height below the 10th centile, broad thorax, first degree
relative with suggestive NS and one of the following: developmental delay,
undescended testes or lymphatic dysplasia.
 Retrospective phase: the patient database of the Division of Human Genetics,
UCT, was reviewed by the candidate. All patients seen at our clinic in the last
two years with a clinical diagnosis of NS were filtered. Individual patients in
the case of adults, and parents (or guardians) in the case of children, were
contacted by telephone and requested to attend one of the special
consultations that were organised for the purpose of the present study. Each
proband’s folder was revisited and a careful clinical assessment was repeated
by the candidate, together with the study supervisor. A questionnaire was
administered to selected patients who consented to the study.
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 Prospective phase: every new patient attending the routine adult or paediatric
genetic clinic during the recruitment period and meeting the clinical diagnostic
criteria of NS was directly enrolled into the study, if the candidate and the
supervisor were both present. Alternatively patients with suggestive features
were invited to attend one of the special consultations organised for the
purpose of the study.
2.2.4.2 PHENOTYPING
FAMILIES’ PEDIGREE
Family history of NS was assessed using a three-generation pedigree for each
selected proband. The pedigree was extended on the affected side of the family
whenevernecessary. A special enquiry was made on cardiovascular abnormalities,
developmental delay or learning difficulties, and physical features of NS such as
short stature, webbed neck and pectus deformities of the chest.
ANTENATAL FEATURES
Antenatal history of each selected patient was carefully recorded whenever possible.
Information was collected from the parents, guardians, hospital files or any other
available family archive. A focus was made on maternal illnesses, exposure to
teratogens,and ultrasound abnormalities including soft markers and major foetal
structural defects.
NOONAN DYSMORPHOLOGY ASSESSMENT
An extensive phenotyping of the probands was performed, allowing documentation
of full clinical characteristics, by the candidate with additional examination with a
consultant medical geneticist from the Division of Human Genetics, Faculty of Health
Sciences, UCT. Every organ system was assessed, with special focus on those
reported to be frequently affected in NS(Van der Burgt 2007; Romano et al. 2010;
Roberts et al. 2013). Photographs of some proband were taken with their consent.
Recommended basic initial investigations in NS, including laboratory testing and
imaging were reviewed and completed as needed for each selected proban
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CARDIAC EVALUATION
Echocardiograms and ECGs were routinely obtained for each selected patient
through formal cardiac assessmentsby specialist cardiologists, either at RCWMCH
for paediatric patients or GSH for adult patients. Data was collected from hospital
files for those who had had cardiac evaluation prior to their medical genetics
assessment. Cardiac assessment was systematically requested for patients with
unknown cardiac phenotype. While echocardiograms were evaluated for CHDs (e.g.
Pulmonary Valve Stenosis, HCM),ECGs were evaluated for abnormalities known to
be associated with NS (e.g. left axis deviation) (Appendix 1).
BIOLOGICAL INVESTIGATIONS
Investigation of bleeding diathesis was done for each selected patient. A coagulation
screen, including completeblood count, PT and aPTT was obtained either from
patient’s hospital files or by new request.
2.3 MOLECULAR METHODS
Part of our cohort of NS patients was genotyped for the coding sequences of a panel
of 14 genes, including A2ML1, BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2,
NRAS, PTPN11, RAF1, RIT1, SHOC2, SOS1 and SPRED1. Deletion/duplication
analysis was not performed in this study.
2.3.1 SAMPLE COLLECTION AND DNA EXTRACTION
Peripheral blood (2-5ml) was collected from each selected proband at the
recruitment sites, after informed consent. Genomic DNA was subsequently isolated
from peripheral blood samples at the NHLS- Molecular Genetics Laboratory,
GSH,following the manufacturer’s instructions (Maxwell®16 Blood DNA purification
kit, Promega, Madison, WI 53711, USA).
2.3.2 DNA QUALITY CONTROL
A total of seventeen (n=17) DNA samples were checked for their purity,
concentration and integrity (see summary in Table 5).
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a. DNA purity and quantification
The purity (260/280 ratio) and initial concentration of the DNA samples were
assessed using the NanoDrop® ND-1000 spectrophotometer (Thermo Fisher
Scientific) and its associated software, following standard procedures.
DNA samples were subsequently diluted using SABAX water to 50ng/uL according
to Nanodrop concentrations, except when otherwise indicated. After calibration of the
Qubit® 3.0 fluorometerwith standards (Thermo Fisher Scientific), DNA sample
concentrations were calculated using the Qubit® dsDNA HS (High Sensitivity) Assay
(Thermo Fisher Scientific) according to the manufacturer’s protocol.
b. DNA integrity
To assess the integrity of DNA samples following the process of DNA isolation which
is subject tomechanical damage, agarose gel electrophoresis was performed (Figure
3). A 1% (w/v) agarose gel (1X Tris-borate-EDTA buffer) was prepared.
Approximately 100ng of each DNA sample (based on Qubit values) in addition to
5uL loading buffer (40% (w/v) sucrose, 0.125% (w/v) bromophenol blue) was
analysed. The GeneRuler 100bp Plus DNA Ladder was chosen as the molecular
weight marker (MWM) (Thermo Fisher Scientific). Electrophoresiswas performed at
110V for 30 minutes.
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Figure 3: DNA integrity gel of NS patients
A1% (w/v) agarose gel electrophoresis product shows the resolution of each
selected DNA sample. Lane numbers correspond to the respective patients.
 The gel at the top shows, from left to right: lane 1= GeneRuler 100bp Plus DNA
Ladder molecular weight marker (MWM); lane 2= sample 02; lane 3 = sample 10;
lane 4 = sample 18; lane 5 = sample 12; lane 6 = sample 08; lane 7 = sample 13;
lane 8 = sample 01; lane 9 = sample 14 and lane 10 = sample 07.
 The gel at the bottom shows, from left to right: lane 1= MWM; lane 2 = sample
06; lane 3 = sample 05; lane 4 = sample 04; lane 5 = sample 15; lane 6 = sample
03; lane 7 = sample 16; lane 8 = sample 09; lane 9 = sample 11and lane 10 =
empty
MWM        2          10 18 12 8           131         147






Table 5: Summary of DNA Quality Control methods
Sample ID Nanodrop Dilution Qubit Integrity gel








01 130.86 1.85 1.75 19 31 60 2 6
02 38.88 1.91 1.77 - - No dilution 33.6 3 5
03 55.4 1.87 20.76 - - No dilution 48.1 2 6
04 211.68 1.86 2.62 12 38 56 2 6





06 149.42 1.88 2.7 17 33 53 2 6
07 64.03 1.88 2.63 39 11 48.9 2 6
08 277.67 1.86 2.27 9 41 52 2 6





10 58.42 1.88 -10.33 43 7 36 3 5
11 112.87 1.94 1.8 22 28 36.2 3 5





13 300.47 1.86 2.09 8 42 58 2 6





15 116.03 1.85 2.25 22 28 44.2 2 6
16 98.29 1.88 3.24 13 12 final volume
25uL
50 2 6
17 1922.65 1.84 1.75 1 49 10.3 10 -
2.3.3 Ion TorrentNEXTGENERATION SEQUENCING
A total of sixteen (n=16) DNA samples were selected based on quality, purity and
integrity, and genotyped using targeted NGS approach.
a. Primer Design
Online pre-designed primers for Ion AmpliSeq Noonan Research Panel (Nelen et al.
2014)were ordered using the Ion AmpliSeq Designer v5.1 software (Life
Technologies, Carlsbad, CA). The primers amplify the coding sequences of the 14
genes mentioned before, which have been selected based on their role in NS,
supported by recent published literature. The Ion AmpliSeq Noonan Research panel
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(Nelen et al. 2014) is predicted to cover 100%, in 268 amplicons.  Amplicons are
split between two multiplex pools.
b. TaqMan RNase P ASSAY
Prior to library preparation, genomic DNA samples were quantified using TaqMan
RNase P assay (ThermoFisher Scientific, USA), according to the manufacturer’s
protocol (https://tools.thermofisher.com/content/sfs/manuals/MAN0007732_Sample
Quant_AmpliSeq_TaqManRNaseP_UB.pdf).
 Preparation of the standard curve with control DNA
Quantitative PCR (qPCR) was used to confirm the amplification efficiency of each
genomic DNA sample and to obtain a more accurate estimation of concentration.The
TaqMan RNase P assay (Thermo Fisher Scientific), which is recommended for NGS,
was used. In order to generate a standard curve, a serial dilution was prepared with
nuclease-free water for the control included in the kit, ranging from 5ng/uL to
0.15625ng/uL.
 DNA samples dilution, master mix preparation and real time PCR reaction
A 1:20 dilution of each genomic DNA sample with nuclease-free water was
independently prepared, based on Qubit values. A PCR Master Mix was
subsequently prepared for a 96-well plate and lastly, genomic DNA samples and
controls were amplified in duplicate in 10uL reaction volumes according to the
manufacturer’s protocol, using a CFX96 (Bio-Rad) thermal cycler.
c. Library Preparation
DNA was diluted to 1ng/uL with nuclease-free water in preparation for sequencing.
Library preparation was performed at the sequencing laboratory of the Division of
Human Genetics of UCT, using the Ion AmpliSeq Kit for Chef DL8 according to
manufacturer’s protocol (https://tools.thermofisher.com/content/sfs/manuals/MAN001
3432Ion_AmpliSeq_Library_Prep_on_Ion_Chef_UG.pdf). From this step of the
procedure, only sixteen (n=16) DNA samples were includedas per the Ion AmpliSeq
Kit for Chef DL8 protocol. The selection of samples to be finally included was based
on their quality, purity and integrity. The remaining DNA samples were archived for
future sequencing. The steps followed are shown in Figure 5.
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Preparation of the genomic DNA samples (n=16)
V
Creation of a sample set on the Ion Torrent Server
V
Addition of amplicons pools to positions A and B of the reagents cartridge
V
Addition of15ng genomic DNA to the Ion Code barcode plate
V
loadingand initialisation ofthe Ion Chef instrument
V
Ion Chef run initiation
V
Unloading of the Ion Chef Instrument at the end of the run, after 7 hours
Figure 4: Workflow summarizing library preparation on the Ion Chef
d. Template Preparation
The Ion Chef was used for templating of the Ion Sphere particles, clonal
amplification and loading of the sixteen libraries on a 316 PGM chip (Ion PGM
Hi-Q Chef Kit).
e. DNA Sequencing
Sequencing was performed on the Ion PGM (Thermo Fisher Scientific) (see run
summary in Figure 5).
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Figure 5: Run summary
Note,82% loading efficiency of the PGM 316 chip, of which 62% of the ion sphere
particles were clonal.  After the removal of 8% low quality reads, a final number of
almost 3 GB of usable reads was obtained.
2.3.4 BIOINFORMATICS ANALYSIS
The Ion Reporter bioinformatic pipeline of the Ion Torrent Suite and the Ion Reporter
cloud-based software (ThermoFisher Scientific) was used to perform basic workflow
for NGS, including quality assessment, readalignment, variants identification, variant
annotation, visualisation, prioritisation, and filtering.From the usable reads, 99%
could be mapped to the human reference genome used (Homo sapiens, hg19, build
37.2). Owing to the challenges in NGS data analysis and interpretation, additional
bioinformatic analysis was executed including variant filtering, prioritisation and
interpretation, based on the VCF file generated by the Ion Reporter software. This
was achieved with bioinformatics support from a research officer at the genomic
laboratory of the Division of Human Genetics of UCT.Manual filtering and
prioritisation of generated variants was performed using:
 Filtered variant frequencies for our dataset: only variants with a
frequency < 0.75 in our dataset were selected, assuming that variants
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present in the dataset with a frequency > 0.75 would be likely
sequencing errorsthan real disease-causing variants;
 Zygosity of variants: homozygous variants were systematically
excluded as NS is caused by heterozygous variants;
 Variant’s function: synonymous variants were systematically excluded
as no change in protein function was anticipated;
 Variants labelled “non-pathogenic” according to ClinVar by the Ion
Reporter software were excluded;
 Variants with a minor allele frequency (MAF)≥0.01 based on the 1000
genome project and 5000 exomes were excluded as they are likely
polymorphism than true disease-causing variants;
 Variant’s location: only exonic variants were selected. Intronic as well
as and 5', 3' UTR variants were excluded.
The pathogenicity of each selected variant was subsequently assessed using online
genomic softwares (www.clinvar.com;www.decipher.sanger.ac.uk; IGV viewer;
www.mutationtaster.org; www.ensembl.org), existing online databases for NS
(www.nseuronet.com) and published literature on NS-associated variants for each
selected gene of our panel. Intronic variants and variants located in intron/exon
boundaries were not specially investigated.
2.3.5 SANGER SEQUENCING VALIDATION
Due to the financial and time limitations, pathogenic variants identified by NGS could
not be validated with Sanger sequencing and/or in silico pathogenicity tools analysis
in this study. This will be done in the future.
2.4 GENOTYPE-PHENOTYPE CORRELATIONS METHODS
The relationship between the genotype and the phenotype of all mutation-positive
patients was established as follows:
 The phenotype of each mutation-positive patient was reviewed, including
photographs when available;
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 Phenotypes were grouped by genes involved and comparative description of
NS key clinical characteristics was achieved, based on international medical
literature.
2.5 STATISTICAL ANALYSIS
A questionnaire constructed in English, with Afrikaans and Xhosa translations was
administered to each selected proband. All statistical analysis was performed using
STATA (Version 13.1; Stata Corp, College Station, Texas, USA).
 Descriptive statistics
Descriptive statistical analysis was used to characterise the total sample and
relevant genotype-phenotype correlations. Continuous variables were described
using means (standard deviations) or medians (interquartile ranges) depending on







From January 2015 to January 2017, a total of twenty six (n=26) patients were
included in this study. The majority werechildren (n=20; 77%) with a median age at
clinical diagnosis of 4.5 years (range: 1month - 51years) (Figure 6). There was a
slight predominance of males with 57.7% (n=15) of males against 42.3% (n=11) of
females (sex ratio: 1.36).
Figure 6: Age distributionin the cohort of 26 patients with a clinical diagnosis of NS
The majority of patients was clinically diagnosed in childhood (1-12 years) (n= 15;
57.7%). Only one patient was diagnosed in neonatal period. There was a gap
between childhood and adulthood with no patient diagnosed in adolescence.
Figure 7: Ancestry distribution in the cohort of 26 patientswith a clinical diagnosis of
NS.
Individuals of mixed-ancestry background were the most represented group (53.8%),




Half (n=13) of patients had a family history suggestive of NS, while 42.3% (n=11) of
patients were likely simplex cases. The family history was unknown in two adopted
patients. Of the 13 patients with a family history of NS, 9 were unrelated.
3.2.2 PHENOTYPIC DESCRIPTION
3.2.2.1 Antenatal Features
Antenatal abnormalities were present in 23.1% (n=6) of patients (Table 6), while no
abnormalities were found in 50% (n=13) of patients. Antenatal data was not available
in the remaining cases (n=6).
Table6: Antenatal abnormalities





Increased Nuchal Translucency 1 3.8
Intrauterine Growth Restriction (IUGR) 1 3.8








Prematurity was recorded in 15.4% (n=4) of cases.The mean birth weight was
2582.65g ±1276.1SD (range: 2080-4420), with the majority of patients (90.9%)
having a birth weight above 2500g. The birth length of patients was not available in
up to12 cases (46.1%); in the remainingcases (n=14), the mean birth length was
48.82 ±3.1SD (range: 43-54).
3.2.2.3 Developmental Milestones
Gross motor milestones were on par for the majority of patients, with ability to walk
before the age of 18 months reported in 61.5% (n=16) of cases. Six (23.1%)patients
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were unable to walk after 24 months. Speech delay was reported in 50% (n=13) of
cases, and information was not available for 6 patients (23.1%).
3.2.2.4 Medical History
One or more major structural defects involving an organ system were present in
69.2% (n=18) of cases. Structural defects involving organ systems other than the
cardiovascular system are listed in Table 7.





Right pulmonary hypoplasia with elevated right diaphragm 1 3.8
Agenesis of the corpus callosum 1 3.8
Fused ribs 1 3.8
Multicystic kidney 1 3.8
Duplex Left collecting system 1 3.8
Undescended testes 7 46.7 males
Pyloric stenosis 1 3.8
Umbilical hernia 1 3.8
3.2.2.5 Surgical History
A total of 19 (73.1%) patients had undergone at least one surgical procedure since
birth, cardiovascular surgery being the most common (42.3%), followed by
orchidopexy (11.5%). Indications for surgery are summarized in Table8.





Heart defect 11 42.3
Undescended testes 3 11.5
Bilateral carpal tunnel syndrome 1 3.8
Tonsillectomy 1 3.8
Desmoid cyst 1 3.8
Spontaneous pneumothorax 1 3.8
Inguinal hernia 1 3.8
Umbilical hernia 1 3.8
Pyloric stenosis 1 3.8
Appendicitis 1 3.8
PEG tube insertion ( swallowing difficulties) 1 3.8
Eye surgery (strabismus) 1 3.8
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3.2.2.6 Craniofacial Features
The craniofacial features associated with NS were widely variable among our
patients. Some patients presented withtypical craniofacial dysmorphism (Figure 6),
while others had a rather mild craniofacial phenotype. The most frequent feature was
epicanthic folds, present in65.4% of patients, followed by low-set ears (57.7%). The
craniofacial features found in our cohort are summarized in Table 9. Comparisons of
the craniofacial features by age and ethnic groups are shown in Tables 10 & 11.
Figure8:Face and Neck of a 3-year-old boy with NS.
Typical craniofacial dysmorphic features occurring in children with NS.
Note: Elongated face;impression of large head;curly hair; widely spaced eyes; epicanthic
folds; ptosis;tall forehead;low-set ears; short, wide and depressed nasal root; short and
webbed neck.






Tall & prominent forehead 12 46.1
Elongated face 12 46.1
Coarse face 5 19.2
Myopathic face 5 19.2
Macrocephaly 4 15.4
Thin & transparent skin 2 7.7
Epicanthic folds 17 65.4
Ptosis 12 46.1
Widely spaced eyes 8 30.8
Downslanting palpebral fissures 7 26.9
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Eyes Thick hooded eyelids 6 23.1
Blue green irises 3 11.5
Arched and diamond-shaped eyebrows 3 11.5
Others Upslanting palpebral fissures 1 3.8
Deep-set eyes 1 3.8
Ears
Low set 15 57.7
Posteriorly rotated 14 53.8
Thick helices 12 46.1
Prominent lobe 1 3.8
Nose
Short and broad 13 50
Depressed root 13 50
Upturned tip 7 26.9
High & thin bridge 5 19.2
Prominent noso-labial fold 3 11.5
Mouth
High wide picks of the vermilion 10 38.5
Micrognathia 8 30.8
Deeply grooved philtrum 6 23.1
Long philtrum 1 3.8
Neck Short neck 12 46.1
Webbing 5 19.2
Excessive nuchal skin 2 7.7
Other Malar hypoplasia 1 3.8
Table 10: Comparison of craniofacial features between age groups
Characteristic craniofacial features were less distinctive in new-borns (n=1) and
adults (n=6). Features were more characteristic in infants (2-12 months), with the
most common being widely spaced eyes, epicanthic folds, ptosis and broad nose









Macrocephaly 1(100%) 2(50%) 0 0
Tall and prominent forehead 1(100%) 2(50%) 8(53.3%) 1(16.7%)
Coarse face 0 1(25%) 2(13.3%) 5(83.3%)
Elongated face 1(100%) 1(25%) 6(40%) 4(66.7%)
Widely spaced eyes 0 3(75%) 5(33.3) 0
Epicanthic folds 1(100%) 3(75%) 9(60%) 3(50%)
Ptosis 0 3(75%) 10(66.7) 0
Low-set ears 1(100%) 2(50%) 9(60%) 3(50%)
Short, broad, depressed nasal
root
0 3(75%) 12(80%) 3(50%)
Prominent naso-labial folds 0 0 2(13.3%) 2(33.3%)
High wide peaks of the
vermilion
0 2(50%) 11(73.3) 2(33.3%)
Short neck 0 2(50%) 8(53.3%) 2(33.3%)
Webbed neck 0 1(25%) 3(20%) 1(16.7%)
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Table 11: Comparison of key dysmorphic features between ethnic groups
Key dysmorphic featureswere less marked in Caucasian patients (n=2) followed by Indians
(n=2). Black Africans presented with the most dysmorphic features. Epicanthic folds, ptosis
and low-set ears were most common in Black Africans compared to other ethnic groups.
Short stature was present in >87% of patients in all ethnic groups, except for Caucasians









Widely spaced eyes 2(25%) 5(35.7%) 0 1(50%)
Ptosis 6(75%) 7(50%) 0 0
Epicanthic folds 7(87.5%) 9(64.2%) 0 1(50%)
Low-set ears 6(75%) 7(50%) 1(50%) 1(50%)
Webbed neck 3(37.5%) 1(7%) 1(50%) 0
Short stature 7(87.5%) 12(87.5%) 0 2(100%)
3.2.2.7 Cardiovascular features
At least one cardiac abnormality was identified in 65.4% (n=17) of patients (Figure
7). The most common congenital heart defect was Pulmonary Valve Stenosis, found
in 34.6% of cases.Hypertrophic Cardiomyopathy (HCM) was identified in 19.2% of
patients and left axis deviation on ECG was found in 23.1% of cases.
Figure 9: Profile of Cardiac Defects in 26 Patientswith Noonan Syndrome
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3.2.2.8 Other clinical features
The clinical featuresfound in our cohort of NS patients,excluding cardiac
abnormalities (Figure 7),are summarized in Table 12.





Short stature 21 80.8
Central Nervous
System






Auditory Conductive hearing loss 3 11.5
Sensorineural hearing loss 1 3.8
Oral & Dental
High arched palate 11 42.3
Dental malocclusion 11 42.3
Dental caries 2 7.7
Widely spaced teeth 1 3.8
Overcrowded teeth 1 3.8
Chest
pectus excavatum (PE) 6 23.1
Pectus carinatum (PC) 4 15.4
PC superiorly & PE inferiorly 1 15.4
Musculoskeletal
(other than chest)
Spine Scoliosis 5 19.2
Lumbar hyperlordosis 1 3.8
Limbs
Cubitus valgus 2 7.7
Talipes equinovarus 1 3.8
High arched feet sole 1 3.8
Joints Hyperlaxity 3 11.5
Contracture 2 7.7
Other 5th finger clinodactyly 1 3.8
Overlapping 2-3 toes 1 3.8




Poor suck & prolonged
feeding time
3 11.5
Severe feeding issues with
tube-feeding for > 3 weeks
3 11.5




Pyloric stenosis 1 3.8
Genitourinary
Undescended testis 7/15 males 46.7
Duplex left collecting system 1 3.8
Multicystic kidney 1 3.8
Thick curly hair 15 57.7
Cafe-au-lait spots 9 34.6
Pigmented naevi 3 11.5
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Dermatology Skin Keratosis pilaris atrophicans
faciei
1 3.8
Axillary freckling 1 3.8
Hypopigmented facial lesion 1 3.8
Haematology &
Oncology
Bleeding diathesis (easy bruising) 14 53.8
Abnormal PT & PTT 1 3.8
Mild thrombocytopenia 1 3.8
Solid tumour (Desmoid cyst) 1 3.8




Learning difficulties 11 42.3
Mild intellectual disability 7 26.9







Molecular genetic analysis wasexecuted on 16 genomic DNA samples out of the 26
collected. Targeted NGS of a panel of fourteen genes was performed in all selected
samples using Ion Torrent instruments, with screening of all the exons, introns and
intron-exon boundaries.
3.3.1 VARIANTS PROFILE
Of the 16 samples from apparently unrelated patients analysed, variants predicted to
be pathogenic were detected in 7 (43.7%) cases (Table 13). These patients included
6 males (86%) and 1 female (14%). Five (5/7; 71%) were detected in patients with
family history suggestive of NS and 2(2/7; 28%) were apparently de novo(Figure 8).
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Table 13: Characteristics of the predicted pathogenic variants detected
Of the seven mutation-positive patients identified, 3(42.8%) had a pathogenic variant
in CBL, 2(28.6%) in PTPN11 and 2(28.6%) in MAP2K1.








chr15:66729181 NM_002755.3 MAP2K1 3 c.389A>G p.Tyr130Cys missense Case#10
chr15:66727484 NM_002755.3 MAP2K1 2 c.200A>C p.Asp67Ala missense Case#15
chr11:119170290 NM_005188.3 CBL 16 c.2520T>G p.Cys840Trp missense Case#7
chr11:119156193 NM_005188.3 CBL 11 c.1858C>T p.Leu620Phe missense Case#13
chr11:119169161 NM_005188.3 CBL 15 c.2345C>T p.Pro782Leu missense Case#14
chr12:112926890 NM_002834.3 PTPN11 13 c.1510A>G p.Met504Val missense Case#2
chr12:112926876 NM_002834.3 PTPN11 13 c.1496C>T p.Ser499Phe missense Case#3
Figure 10: Age distribution in mutation-positive patients
The clinical diagnosis of NS was made in patients with pathogenic variants in
MAP2K1 earlier than in patients with pathogenic variants in PTP11 and CBL.
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Figure 11: Family segregation of NS in patients (n=7) with positive results
The majority of patients (n=5; 71%) with a positive result after molecular analysis has a
family history suggestive of a familial segregation of NS.
Figure 12: Summary of the clinical and molecular genetic data
This flowchart showssomesteps in our data processing.
Total number of NS
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3.4.1 PHENOTYPE OF MUTATION-POSITIVE PATIENTS
The table below (Table 14) describes the association between pathogenic variants
detected in our cohort and their related phenotype.
Table 14: Clinical characteristics of 7 patients with positive molecular testing
 *= Noonan syndrome; **= Cardiofaciocutaneous syndrome; ***= Intellectual disability;
x= No abnormality; ?= Unknown; √= Abnormality present; N/A= Not applicable.
 The squares indicate features reported in the literature to be positively (black) or
negatively (blue) associated with the presence of a pathogenic variant in each
corresponding gene.
 The variant identified in Case#7 has been associated with Cardiofaciocutaneous
Syndrome, a RASopathy sharing several features with NS.





























































































Neck & Thoracic features
Webbed /short neck















Congenital Heart Defect& ECG
Pulmonary valve stenosis
Hypertrophic cardiomyopathy
Coarctation of the aorta

















































































































Strabismus x x x x x √ x
Auditory abnormalities
Conductive hearing loss x x √ x x x x
Renal abnormalities



























































































3.4.2 COMPARATIVE DESCRIPTION OF CHARACTERISTICS
Table 15 presents and compares the mean age at diagnosis,as well as key NS
clinical characteristics among mutation-positive patients with respect to the gene
involved.
Table 15: Genotype-phenotype comparisons of the 3 genes identified
Patients with pathogenic variants in MAP2K1 presented with more typical clinical features of
NS, followed by patients with pathogenic variants in PTPN11. Clinical features were more







Mean age at Diagnosis (year) 3.3 11.1 1
Positive family history 2(100) 2(66.7) 1(50)
Antenatal features 0 0 2(100)
Short stature 2(100) 3(100) 2(100)
Typical dysmorphic features 2(100) 1(33.3) 2(100)
Webbed/Short neck 2(100) 3(100) 2(100)
Pectus deformity of the chest 0 2(66.7) 2(100)
Congenital Heart Defects 2(100) 1(33.3) 2(100)
Pulmonary valve stenosis 1(50) 0 1(50)
Hypertrophic cardiomyopathy 1(50) 1(33.3) 0
Coagulopathy 2(100) 1(33.3) 1(50)
Skin features 0 1(33.3) 2(100)
Intellectual disability 0 1(33.3) 2(100)
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CHAPTER 4





This study is, to the best of our knowledge, the first of its kind to investigate a cohort
of NS individuals from clinical and molecular perspectives, with the use of NGS
technology in South Africa. It provides insights into the spectrum of clinical features
and pathogenic variants in South African individuals affected by NS.Furthermore,
this study supports the necessity of establishing a local moleculardiagnostic testing
for RASopathies in the public health sector in South Africa.
4.1.2 SOCIODEMOGRAPHIC CHARACTERISTICS
Sociodemographic analysis of the cohort revealed a male predominance. Of the 26
patients included in this study, 57.7% were males and 42.3% were females, with a
sex ratio of 1.36. This  is consistent with  the results of a European family study on
NS, which investigated 49 unrelated European families and showed a significant sex
ratio bias in NS transmission (>1) favouring transmission to males(Tartaglia et al.
2004).Similarly, in a study of  cardiovascular features in 293 individuals affected with
NS, Prendiville and collaborators reported that 60% of the affected patients were
male(Prendiville et al. 2014).
Individuals of mixed race ancestry were the most represented ethnic group (53.8%),
followed by black Africans (30.8%), in keeping with ancestrydistribution in the
Western Cape Province where the population is made up of 48.7% of individuals of
mixed-race ancestry and 32.8% of black Africans (Statistics South Africa,Census
2011).
In our cohort, the age atclinical diagnosis of NS ranged from 1 month to 51 years
with a median age at diagnosis of 4.5 years. The most represented age group was 1-
12 years. Only one individual was diagnosed in the neonatal period and no diagnosis
was made in the age group 12-18 years.This result may be explained by at least
three factors: Firstly, in the local environment, not all pregnant womenhave
ultrasound scans throughout pregnancy. For those in the cohort who have had one
or more ultrasound scans, either no abnormality was found (50%), or even when
prenatal features suggestive of NS were present(e.g. polyhydramnios, increased
nuchal translucency, renal anomalies or Pulmonary Valve Stenosis),possible
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association with NS was not always established by clinicians.In the absence of
prenatal molecular diagnostic testing for NS in South Africa, recognition of prenatal
features of NS could at least have contributed to increasethe proportion of patients
diagnosed in the neonatal period. In fact, with a prenatal detection rate of 17.3%,
Croonen and collaborators recommended NS testing in the presence of one or more
of lymphatic abnormalities, renal anomalies, polyhydramnios and cardiac anomalies,
in addition to an increased nuchal translucency(Croonen et al. 2013). Secondly,
inthelocal setting, the limited clinical diagnostic ability of many clinicians untrained in
dysmorphology, coupled with the scarcity of trained medical geneticists often results
in initial misdiagnosis, followed bya late diagnosis, typically in childhood (1-12 years),
after several hospital admissions and referral to medical genetics. Finally, in view of
the age-relatedvariability in NS physical features, with subtlety of craniofacial
features in many adults (Van der Burgt 2007; Roberts et al. 2013), moderate-to-
severely affected individuals would be expected to be diagnosed by childhood, and
mildly affected individuals in adulthood following either cardiac decompensation or
cascade screening after the birth of an affected child. In our cohort, all adult patients
were diagnosed with NS during their assessment in the Cardiology department.
4.1.3 FAMILY SEGREGATION
It is widely known that an average of 60% of individuals affected with NS have, in
prospect or retrospect, a positive family history of NS. In our cohort, 50% of patients




Developmental milestones were variable among our patients. Achievement of gross
motor milestones was globally earlier than language milestones.In this study, 61.5%
of patients were able to walk by the age of 18 months, slightly above the average of
21 months reported in a large study of the natural history of NS conducted by
Sharland and collaborators(Sharland et al. 1992). Half (50%) of our patients were
able to speak simple two-word sentences before the age of 24 months. A recent
systematic review of the neuropsychological functioning of individuals affected with
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NS, reported an average age of simple two-word sentences from 31 to 32 months
(Pierpont 2016). The difference between our results and the literature may be
explained by both the small size of our cohort and the fact that only screening
measures were used. Application of comprehensive diagnostic assessments may
have produceddifferent results.
FACIAL DYSMORPHOLOGY
Recognition of dysmorphic features can be very powerful in the clinical diagnostic
process of NS (Van der Burgt 2007).  The dysmorphology in NS varies with age and
somewhat between ethnic groups. In a recent international collaborative study
investigating NS-associated dysmorphic features in 125 individuals from diverse
populations, we have demonstrated that regardless of the age and ethnic
background, clinical findings in NS are similaracross ethnic groups. The three most
common dysmorphic features, present in >70% of individuals were: widely spaced
eyes (≥80%), low-set ears (>80%) and short stature (>70%). The two features found
different among ethnic groups were ptosis and webbed neck. Ptosis was less
common in black Africans (63%) while webbed neck was less common in Asians
(Kruszka et al. 2017). The present study included black Africans, Caucasians,
Indians and mixed-race ancestry individuals. The most common feature was
epicanthic folds (65.4%), followed by low-set ears (57.7%). Widely spaced eyes were
present in only 30.8% of patients, ptosis in 46.1% and short stature in 80.8%. Black
Africans were found to have the most distinctive features; epicanthic folds, ptosis
and low-set ears were most common in black Africans compared to other ethnic
groups.Our small cohort size could explain the statistical difference between this
study and the previously reported study (Kruszka et al. 2017). Comparison of
features between age groups showed that typical craniofacial features were less
distinctive in the neonatal periodand adulthood and more characteristic in infancy (2-
12 months), in accordance with the medical literature (Roberts et al. 2013). A special
point to note on the dysmorphology findings in this study is the high frequency of
epicanthic folds, which maysimply represent a confounding factor. In fact, previous
studies have reported epicanthic foldsto be very common in the general black South
African population (Christianson et al. 1995).
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CARDIOVASCULAR PHENOTYPE
NS is the second most common cause of syndromic congenital heart defects (CHDs)
after Down Syndrome (Marino et al. 1999). CHDs are reported in 50-80% of
individuals affected with NS (Hickey et al. 2011; Prendiville et al. 2014). Early
detection and management of cardiovascularanomalies arecritical as they
representthe major cause of mortality. In our cohort at least one CHD was identified
in 65.4% of patients. Pulmonary Valve Stenosis was the most common CHD as
reported in previous studies, but with a lower incidence (34.6%).In a retrospective
and descriptive study conducted by Prendiville and collaborators in Boston, USA,
investigating the spectrum of cardiac anomalies in 293 NS patients, CHD was
reported in 81% of patients. Pulmonary Valve Stenosis was the most common CHD,
reported in 57% of patients and HCM was reported in 16% of patients.
The lower incidence of Pulmonary Valve Stenosis in our study could be well
explained by the small size of our cohort. However, it could be a specificityof the
South African population in relation to the genotype of affected individuals with NS in
this environment.There is a thought that bias may exist in the published frequency of
CHD in NS as, in the past, the presence of CHD was required by many clinicians to
establish the clinical diagnosis of NS (Allanson & Roberts 2001).We believe that
studying a larger South African cohort mayaid to make a more convincing
conclusion.
4.1.5 MOLECULAR ANALYSIS
In order to maximize the detection rate of NS in the cohort investigated in this study,
we used the approach of targeted NGS, on the Ion PGM platform with Ion AmpliSeq
Noonan Research Panel (ThermoFisher Scientific, USA). This multigene panel
allowed for simultaneous sequencing of fourteen causative genes known to be
associated to NS, based on recent medical literature (Nelen et al. 2014). A total of
sixteen DNA samples from 16 unrelated patients were analysed. Seven variants
predicted as pathogenic were detected in 3 genes (7/16 = 43.7% of detection rate),
including CBL (3/16 = 42.8%), PTPN11 (2/16 = 28.6%) and MAP2K1 (2/16 =
28.6%).All the variants detected were missense variants, in keeping with previous
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studies (Tartaglia et al. 2002; Nava et al. 2007; Martinelli et al. 2010). The detection
rate of >70% is anticipated when using a comprehensive multigene panel testing or
WES (Aoki et al. 2016). In our cohort, however, the detection rate was 43.7% (7/16),
which is similar to that obtained(47.5%) in a comparable study in Italy (Lepri et al.
2014). It is unlikely that inappropriate phenotyping is the reason for our detection rate
(<70%), in view of the particularly stringent patient selection process applied.
Therefore, some patients presenting with typical clinical features of NS had
unexpectedly negative molecular test results. Furthermore, the mutation frequency in
the genes screened in this study, with CBLfound to be the most frequently mutated
gene, is globally deviated from the results of previous similar series. In fact, since the
first report of a molecular NS study  by Tartaglia and collaborators in 2002, PTPN11
has been consistently reported as the most commonly mutated gene in NS,
explaining 50-60% of all NS cases in other population groups(Tartaglia et al. 2002;
Lepri et al. 2014).CBLisreported in the literature as a rare cause of NS, accounting
for < 3% of cases(Martinelli et al. 2010), and MAP2K1 is reported to account for
about 4.2% of NS cases(Nava et al. 2007). The global difference in the mutation
frequency in our study compared to the literature may be explained by the small size
of our cohort. However this result may highlight a specificity of the South African
population.
Interestingly,  one pathogenic MAP2K1 variant (c.389A>G; p.Tyr130Cys) in our
cohort(Table 13, case#10) has been frequently associated with CFC syndrome in the
published literature (Rodriguez-Viciana et al. 2006).This patient was initially
diagnosed with NS at 12 months of age but the diagnosis was subsequently
changed to Costello syndrome (CS) with the progression of clinical features. This
illustrates the challenges of clinical diagnosis of some NS patients, due to
overlapping features with other RASopathies, especially CFC syndrome and CS.
Mutation-positive patients in our study includedunrelated familial caseswith a
proportion of 71%, in agreement with the literature (Allanson & Roberts 2001).
4.1.6 GENOTYPE-PHENOTYPE CORRELATIONS
Genotype-Phenotype correlations have been established for someNS-associated
genes, PTPN11 being the most studied gene.Variability in phenotypic expression,
high genetic heterogeneity and low mutation frequency in a number of NS genes are
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among the difficultiesin establishing comprehensive correlations between known
causative genes or variants and specific phenotypes. In the present study, by
comparing the phenotype associated withthe genes or variants detected based on
twelve key clinical features of NS (Table 15), we found that clinical features were
more characteristic in patients with pathogenic variants in MAP2K1(8/12), followed
by those with pathogenic variants in PTPN11 (6/12). Patients with pathogenic
variants in CBL had less distinctive clinical characteristics. Specifically, an antenatal
feature was present in all the patients with pathogenic variants in MAP2K1 compared
to patients with pathogenic variants in PTPN11 and CBL who had no antenatal
features identified. The above findings could explain the early mean age at clinical
diagnosis in patients with MAP2K1 pathogenic variants (1year) compared to patients
with pathogenic variants in PTPN11 (3.3years) and CBL (11.1years) in our study.
CHDs were present in only 33.3% (1/3) of patients with pathogenic variants in CBL,
none of them presenting with pulmonary valve stenosis. No patient with a MAP2K1
pathogenic variant was found to have HCM.
Genotype-phenotype studies in PTPN11have reported positive association between
short stature, pulmonary valve stenosis, coagulopathy, pectus deformities of the
chest, and PTPN11pathogenic variants. However HCM has been reported as
negatively associated to PTPN11pathogenic variants(Tartaglia et al. 2002; Yoshida
et al. 2004a). With regard to PTPN11 in our study, withthe exception ofHCM which
was present in 50% (1/2) of patients and pectus deformities of the chest, absent in
the two patients, our result (Table 15) is in keeping with the literature.
All the patients with pathogenic variants in MAP2K1 had typical facial dysmorphic
features and skin manifestations of NS in agreement with previously published
studies (Nava et al. 2007; Nyström et al. 2008).
To date, very little is known about genotype-phenotypeassociations in NS with
pathogenic variants in CBL. In an Italian study, Martinelliand collaborators (Martinelli
et al. 2010)reported on 4 individuals (2 sporadic and 2 familial cases) with NS and
pathogenic variants inCBL. Although pectus deformities of the chest, stature >3rd
centile and short or webbed neck were frequently present, the clinical features of the
affected individuals were very variable. Interestingly, one of the patients described
presented with mitral valve insufficiency, which was also found in one of our patients
with pathogenic variants in CBL.
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4.1.7 LIMITATIONS OF THE STUDY
We acknowledge that the present study is not without limitations: 1- With the small
size of our cohort, the results may not necessarily be inferable to the study
population. 2- This is a hospital-based study with a likely ascertainment bias. The NS
phenotype is highly variable in general, even within the same family. Therefore,
individuals with a mild phenotype (e.g. absence of CHD) may not necessarily seek
medical attention and go undiagnosed. Of the six adult patients included in this
study, only two did not present with a cardiac anomaly; the remaining four adult
patients were enrolled during cardiologic assessment of late onset cardiovascular
anomalies strongly associated with NS. 3- Molecular investigations could not be
offered to all the patients included in the study, potentially reducing the power of our
results. 4- Sanger sequencing validation of the detected pathogenic variants was not
performed because of time limitations. Therefore, the presence of false positive
results, while unlikely, could not be excluded. However, some pathogenic variants
detected have been previously reported in the medical literature. All variants
detected were subjected to careful analysis with the available in silico variant
annotation and pathogenicity predictor tools.
4.2CONCLUSIONAND FUTURE PERSPECTIVES
This study represents,to the best of our knowledge, the first clinical and molecular
researchin South African individuals affected with NS.
Our results show that a number of South African paediatric and adult patients are
affected with RASopathies, in particular NS. Clinical characteristics found in affected
individuals are globally similar to those reported in other populations, and careful
phenotyping based on internationally available diagnostic criteria can effectively
facilitate the diagnosis of most NS-affected individuals in South Africa. This study
also demonstrates that targeted NGS with multigene panel testing is a powerful
diagnostic method, which can be successfully applied to the molecular diagnosis of
NS and related conditions in South Africa. The use of targeted NGS allowed for
detection of pathogenic variants in genes infrequently associated with NS in other
populations, which could be missed with the traditional approach or with single gene
screening by Sanger sequencing. While variant distribution in South African NS
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patients may be different from that previously reported in other population groups,
the results of the genotype-phenotype correlations attempted in this study appear to
support the existing data. Study of a larger South African NS cohort is warranted in
order to comfortably infer these results. Finally, our results support the clinical utility
of molecular testing in NS, which can aid early diagnosis, cascade screening,
appropriate genetic counselling and management.Identification of common
pathogenic variants underlying NS and related conditions in South Africans has the
potential to facilitate early diagnosis and allow the study of specific genotype-
phenotype correlations, which in turn can aid clinical diagnosis and support the
development of future therapeutics.
Further work to complete certain aspects of this study is required. This includes
Sanger sequencing validation of all putative pathogenic variants found and a more
in-depth bioinformatics analysis of the NGS files of individuals in whom no exonic
variants were detected, with specific focus on the intron-exon boundaries.
In addition, cascade screening of affected families will be performed and clinical
management arranged when needed. The results of the present study will be used
as support for our plan to establish molecular diagnostic testing for the RASopathies
in the public health sector in Cape Town.
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1- Age:   DOB: Age at diagnosis: …………
2- Race:    Black African = 1 Caucasian = 2      Coloured = 3  Others = 4 
3- Sex:       Male = 1                  Female = 0
4- Country of origin:  South Africa = 1 other = 0 
5- Occupation: scholar/student = 1 = 2      unemployed = 3     employed part-time =4
Employed full-time = 5 
6- Education: tertiary = 1 secondary = 2 Primary = 3    No education = 4 
7- Marital status: single = 1 Married= 2 partnership = 3     divorced = 4
Widow/widowed = 5 
8- Religion : Christian = 1 Muslim = 2    other = 3         Not religious  = 4 




1- Maternal illness : No = 0             Yes = 1 unknown = 2
If yes specify ………………. ………..... = 3
2- Teratogens: Alcohol = 1       illicit drugs = 2        medication = 3
If 2 or 3 specify ………………………... = 3      unknown = 4
3- Others:          Yes (specify)……………… = 1 No = 0
4- Prenatal ultrasound:       normal = 1            abnormalities = 2       No  US = 3
Unknown = 5                          If 2 specify…………………………….. = 4 
B. BIRTH
1- Term of the pregnancy:   < 37 wks = 1 ≥ 37 wks = 2    unknown = 3             
2- Birth weight………     Length………..   Head circumference………..
3- Complications: No = 0             Yes = 1 unknown = 2 
If 1 specify…………………….
IV- DEVELOPMENTAL HISTORY
1- Sat:  < 1y = 1               > 1y = 2     unknown = 3              N/A = 4 
2- Walked:  < 15 m = 1      15-24m = 2     > 24 m = 3     unknown = 4   N/A = 5 
3- Talked: < 24 m = 1 ≥ 24 m = 2 unknown = 3            N/A = 4 
V- PAST MEDICAL HISTORY
A. MEDICAL
1- Structural defect(s):  No = 0    Yes = 1     unknown = 2
If yes specify ……………………………. 
2- Functional defect (s):  No = 0    Yes = 1     unknown = 2
If yes specify ……………………………. 
3- Metabolic defect (s):   No = 0    Yes = 1     unknown = 2
If yes specify ……………………………. 
4- Other:  No = 0    Yes = 1
If yes specify …………………………….
B. SURGICAL
1- History of surgery:  No = 0       Yes = 1       unknown = 2
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2- Type of surgery: brain = 1   eye = 2   chest = 3   heart = 4  abdominal = 5
Spine = 6     hernia = 7    limb (s) = 8     unknown = 9     other = 10   N/A = 11 
VI- CLINICAL DATA
A. CRANIOFACIAL DYSMORPHISM
1- Forehead, face: Tall & prominent forehead = 1   low post hairline = 2
Macrocephaly = 3   elongated face = 4   coarse face = 5   myopathic face = 6
Thin & transparent skin = 7   others (specify)…………………. = 8 
2- Eyes:    hypertelorism = 1   downslanting palp fissures = 2   epicanthal folds = 3
Ptosis = 4   thick hooded eyelids = 5   blue green irises = 6   arched and diamond-
shaped eyebrows = 7   others (specify)………………………… = 8 
3- Ears:    Low-set = 1   post rotated = 2   thick helices = 3   others……….. = 4 
4- Nose:    short & broad = 1   depressed root = 2   upturned tip = 3
High & thin bridge = 4   prominent nasolabial fold = 5   others …………. = 6 
5- Mouth:   deeply grooved philtrum = 1   high wide peaks of the vermilion = 2
Micrognathia = 3   others (specify)………………….. = 4 
6- Neck:    Excessive nuchal skin = 1     Webbing = 2   others……………. = 3 
7- Others:         No = 0 Yes (specify)……………… = 1 
B. GROWTH
1- Short stature: Yes = 1                     No = 2
C. CENTRAL NERVOUS SYSTEM
1- Arnold-Chiari malformation type I:   No = 0      Yes = 1      Unknown = 2
2- Hydrocephalus: No = 0            Yes = 1
3- Others: No = 0 Yes (specify)……………… = 1 
D. OPHTHALMOLOGY
1- Strabismus: No = 0             Yes = 1
2- Anterior segment changes: No = 0             Yes = 1
3- Refractive errors: No = 0             Yes = 1
4- Fundal abnormalities: No = 0             Yes = 1
5- Amblyopia: No = 0             Yes = 1
6- Nystagmus: No = 0             Yes = 1
7- Others: No = 0             Yes = 1(specify)……………………
E. AUDITORY
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1- Sensorineural hearing loss: No = 0             Yes = 1
2- Hearing loss secondary to recurrent otitis media: No = 0             Yes = 1
3- Conductive hearing loss: No = 0             Yes = 1
4- Others: No = 0             Yes = 1 (specify)………………………….
F. ORAL AND DENTAL
1- Dental malocclusion: No = 0 Yes = 1 N/A = 2
2- High arched palate: No = 0             Yes = 1
3- Articulation difficulties: No = 0 Yes = 1 N/A = 2
4- Giant cell lesions: No = 0             Yes = 1
5- Others: No = 0             Yes = 1 (specify)…………………………………...
G. CARDIOVASCULAR
1- Congenital heart defect(s): PS = 1     ASD = 2     VSD = 3     AVSD = 4
PDA = 5      Mitral valve defect = 6   tetralogy of fallot = 7
Others (specify)…………………………. = 8 
2- Hypertrophic cardiomyopathy: No = 0             Yes = 1
3- Electrocardiographic abnormalities:   left axis deviation = 1   negative aVF = 2
Abnormal R/S ratio over the left precordium = 3   abnormal Q wave = 4 
4- Others: No = 0 Yes = 1 (specify)…………...
H. MUSCULOSKELETAL
1- Chest:   pectus carinatum superiorly & pectus excavatum inferiorly = 1
Pectus carinatum = 2   pectus excavatum 3   none = 4 
2- Spine:  scoliosis = 1   other anomalies (specify)…………. = 2      none = 3 
3- Limbs:  Cubitus valgus = 1   Talipes equinovarus = 2   others………...…. = 3 
4- Joints:   contracture = 1   radio-ulnarsynostosis = 2   cervical spine fusion = 3
Hyperextensibility = 4    none = 5 
5- Others: No = 0             Yes = 1 (specify)…………………………
I. GASTROINTESTINAL
1- Feeding difficulties:   poor suck with prolonged feeding time = 1   Very poor suck
and slow feeding with recurrent vomiting = 2   severe feeding problems that
require tube-feeding for ≥ weeks = 3 
2- Hepatomegaly in infancy: No = 0 Yes = 1 unknown = 2 
3- Others: No = 0             Yes = 1 (specify)…………………………
J. GENITOURINARY
1- Undescended testis: No = 0 Yes = 1 N/A = 2 
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2- Renal abnormalities: No = 0             Yes = 1
If Yes specify…………………………………..
3- Sertoli cells dysfunction: No = 0 Yes = 1 Unknown = 2 
4- Others: No = 0             Yes = 1 (specify)…………………………
K. DERMATOLOGY
1- Thick curly hair: No = 0             Yes = 1
2- Pigmented naevi: No = 0             Yes = 1
3- Café au lait spots:    No = 0 Yes = 1 
4- Keratosis pilaris atrophicans faciei: No = 0 Yes = 1
5- Others: No = 0             Yes = 1 (specify)………………………… 
L. HAEMATOLOGY AND ONCOLOGY
1- Bleeding diathesis:   Easy bruising: No = 0      Yes = 1
2- Intrinsic pathway abnormalities:  Factor VIII = 1   Factor XI = 2    Factor XII = 3
others (specify)…………….= 4    none = 5      Unknown = 6 
3- Thrombocytopenia: No = 0             Yes = 1
4- Platelet function abnormalities: No = 0 Yes = 1Unknown = 3 
5- Transient myeloproliferative disorder: No = 0         Yes = 1
6- Leukaemia: No = 0       Yes = 1 (specify)………………..
7- Solid tumours: No = 0           Yes = 1 (specify)…………... 
8- Others: No = 0             Yes = 1 (specify)………………………….
M. LYMPHATIC
1- Lymphedema: No = 0            Yes = 1
2- Lymphangiectasia: No = 0             Yes = 1
3- Chylous effusion: No = 0             Yes = 1
4- Others: No = 0             Yes = 1 (specify)…………………………
N. NEUROLOGY, EDUCATION AND BEHAVIOUR
1- Mild intellectual disability: No = 0             Yes = 1
2- Learning difficulties: No = 0 Yes = 1N/A = 2 
3- Recurrent seizures: No = 0             Yes = 1
4- Behavioural issues: No = 0             Yes = 1(specify)………..
5- Others: No = 0             Yes = 1 (specify)………………………….
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Appendix 2: English version
UNIVERSITY OF CAPE TOWN
DIVISION OF HUMAN GENETICS
INFORMATION SHEET FOR PARTICIPANTS OF RESEARCH STUDY:
“Genetic investigation of South Africans with the Noonan Syndrome Phenotype using
Targeted Next Generation Sequencing”
Introduction
You have been approached to participate in this study because you or your family member
has been diagnosed with probably Noonan syndrome.
People with Noonan syndrome have variable characteristics but do tend to share similar
features such as facial appearance and short stature while still developing. Most adults with
Noonan syndrome are of normal height. Some people with Noonan syndrome may have
other problems, such as heart problems or having difficulties with learning at school.
However, the majority of people with Noonan syndrome can have a relatively normal life if
they are identified early and have regular monitoring for any problems that may arise.
Noonan syndrome is an autosomal dominant disorder. This means that boys and girls can
be affected with equal chance. Often the individual diagnosed with Noonan syndrome is the
first and only individual that is affected in a family, however, once it is in the family it can be
passed on and there are families where many people are affected and have Noonan
syndrome. However, even in the same family, some people can have more severe
symptoms than others and sometimes some people do not have any symptoms at all.
Noonan Syndrome is caused by a change in one of our genes (a piece of DNA), which are
the instructions to make a person. If a father or mother carries a change or mistake in one of
the genes that cause Noonan syndrome, they will have a 50% chance of passing it on to
their son or daughter, causing him/her to have Noonan syndrome
Why are we doing this study?
The aim of this study is to identify individuals who have a likely diagnosis of Noonan
syndrome and perform genetic testing to identify the genetic mistake which has caused this
condition in an individual. The hope is that this will enable us to confirm if you are really
affected or not and to offer better testing in the future for other families affected by Noonan’s
syndrome. The researchers also hope to determine if there are any specific genetic changes
that cause specific features of the condition or not.
What will you ask me to do if I agree to participate in this study?
If you agree to be a part of this study, you will be clinically examined by the doctor
performing this research. In addition, a blood sample will also be taken.
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What will happen to my samples and information?
Your/your child’s blood will be analysed to look for changes in the DNA that would explain
why they have Noonan syndrome. The DNA will be stored for future possible testing. This
information may be used to produce publications but no identifiable data will be used.
Confidentiality
All information given is confidential. All the information gathered during this study will be
safely stored in locked offices or in password protected computers. The DNA will be coded
and the individual working on the sample will not know who it belongs to. The researcher will
not discuss your participation in the research with any other patients or individuals not
involved with your medical care. You may be asked to give permission/consent to publish
photos if these are taken during the clinical examination but this will be your decision.
What are the risks of being involved in the study?
The risk of harm or discomfort expected during this study is not greater than those you
encounter in daily life or during routine medical examinations. The prick of the needle during
blood taking carries the same risks as having bloods taken for any other reason. There may
be some bruising but this is not usually a serious problem.
Are there any benefits to me?
The research may identify the cause of Noonan syndrome in the family, potentially
confirming your/your child’s diagnosis of Noonan syndrome. Should something be identified,
all effort will be made to contact you and explain the result to you in person. This will provide
you with information which can be helpful for you/your child and your family. If a
change/mistake is identified, the family may also be offered genetic testing if they are
interested. Please do inform us if your contact details change during the study period so that
you may be contacted if needed.
Do I have to participate?
No you do not, this is entirely voluntary. If at any time during the study you wish to withdraw
your consent you may do so without any harm to your medical care. You will be treated the
same whether you participate in the study or not. Please feel free to ask your family
members or close friends opinion’s if you need advice before agreeing to participate to the
study.
Please feel free to contact the following people if you have any problems or questions about
the research:
Dr Cedrik Ngongang                                                 Prof Ambroise Wonkam
Tel: 021 406 6698                                                       Tel: 021 406 6307
E-mail: Cedrik.Ngongang@uct.ac.za                          E-mail: Ambroise.Wonkam@uct.ac.za
SrSolomons
Tel: 021 406 6304
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If you have any questions regarding your rights as participants in this research project
please contact Prof M. Blockman, Chair of the Research Ethics Committee of the University
of Cape Town on 021 406 6496.
Appendix 3: English version
UNIVERSITY OF CAPE TOWN
DIVISION OF HUMAN GENETICS
INFORMED CONSENT FOR RESEARCH PROJECT:
“Genetic investigation of South Africans with the Noonan Syndrome Phenotype using
Targeted Next Generation Sequencing”
I, …………………………………………………………………………………………….., hereby
voluntarily consent to my child ……………………………………………….. / My genetic
material being investigated for a disease causing mutation in the genes causing Noonan
syndrome in my family.
INFORMATION REGARDING RESEARCH STUDY:
The objectives of this study are:
1. To identify, families and individual patients with Noonan syndrome;
2. To undertake detailed clinical examination of each selected patient;
3. To perform molecular analysis on a genetic sample from each patient;
4. To establish the Genotype-Phenotype correlation of Noonan syndrome within the
study population
Each participant will have:
1. A clinical examination done by one of the medical doctors at Groote Schuur Hospital
or Red Cross War Memorial Children Hospital
2. A blood sample taken to extract DNA for genetic studies
DNA of people suspected to be affected will be analysed only for mutations in genes causing
Noonan syndrome. If any mutation is found, at risk family members DNA may be tested in
the future for the same mutation. By consenting for this study you are also consenting for
your DNA to be stored for future use. Any further genetic investigations will relate only to
Noonan syndrome.
All results will be delivered to the relevant persons at the end of the study period where
possible. Implications of these results will also be discussed in detail as part of the genetic
counselling process.
By consenting to this research study permission is also granted for publishing of the results.
No identifiable data will be used in publication although photos may be published if your
consent is given. Everything is confidential
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Participation in this study is voluntary and may be withdrawn at any stage, without
any harm to future care.
Signature: ………………………………………… Date: ……………………………
Witness signature: ………………………………. Date: ……………………………
Appendix 4: English version
UNIVERSITY OF CAPE TOWN
DIVISION OF HUMAN GENETICS
ASSENT FOR RESEARCH PROJECT:
“Genetic investigation of South Africans with the Noonan Syndrome Phenotype using
Targeted Next Generation Sequencing”
1. This study is being done by the doctors at the University of Cape Town to try and learn
more about a genetic condition called Noonan syndrome.
2. You and some members of your family have been asked to participate in the study
because Noonan syndrome may run in your family.
3. The doctors are trying to see if they can learn more about how someone with Noonan
syndrome looks, and how it happens. This is so they can better help you and other
people’s families in the future.
4. If you decide to be a part of the study one of the doctors from Genetics will examine you,
and also collect some blood from you.
5. Nothing that will be done will be harmful to you.
6. Everything that is done during the study will be confidential, meaning that no one who is
not a part of the study will know that you participated.
7. You can decide for yourself whether you want to be a part of this study. If you decide to
not be a part of it then no one will be angry with you, and you will still get all the help and
care that you need.
Signature: ………………………………………………… Date: ……………………………..
Witness signature: ………………………………………… Date: ……………………………
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Appendix 5: Xhosa version
UNIVESITHI YASE KAPA
KWICANDELO LWEZOFUZO LOLUNTU
IPHEPHA ELINOLWAZI LWABANTU ABAZOBAYINXALANYE YOPHANDO:
“UphandolwezofuzokuluntulwaseMzantsiAfrikaabaphilanesimo with seNoonan Syndrome”
Igama lam nguCedrik Ngongang, ugqirha wezofuzo ekuqeqesheni kwiYunivesithi yaseKapa,
kwiCandelo loLuntu lweZofuzo.
Uye watyelelwa ukuba uthathe inxaxheba kwe sisifundo ngenxa yokuba wena okanye ilungu
lentsapho yakho sele lufumene i-Noonan syndrome.
Abantu abane-Noonan syndrome baneempawu ezichaseneyo kodwa bathambekele
ukwabelana ngezinto ezifana nokubonakala kwesobuso kunye nokuba mfutshane
ngokwesiqu ngelixa besakhulayo. Uninzi lwabantu abadala abaneNoonan syndrome luye
lubenesiqu esiqhelekileyongokobude. Abanye abantu abanesifo seNoonan syndrome
banokuba nezinye iingxaki, ezifana neengxaki zentliziyo okanye ubunzima bokufunda
esikolweni. Nangona kunjalo, uninzi lwabantu abane-Noonan syndrome banokuba nobomi
obuqhelekileyo ukuba babonwa ngokukhawuleza kwaye bajongwe rhoqo naziphi na iingxaki
ezinokuvela.
I-Noonan syndrome yiAutosomal dominant disorder. Oku kuthetha ukuba abafana kunye
namantombazana banokuchaphazeleka ngamathuba alinganayo. Ngokuqhelekileyo umntu
ofunyanwe yi-Noonan syndrome ngumntu wokuqala kunye nomntu wokuphela
ochaphazelekayo kwintsapho, nangona kunjalo, xa ikwintsapho ingadluliselwa kwaye kukho
iintsapho apho abantu abaninzi banokuchaphazeleka sesisigulo. Nangona kunjalo,
kwintsapho enye, abanye abantu banokuba nezibonakaliso ezinzima kunabanye kwaye
ngamanye amaxesha abanye abantu abanayo nayiphi na impawu. I-Noonan Syndrome
ibangelwa lutshintsho kwelinye lezityalo zethu (isicatshulwa seDNA), eziyimigaqo yokwenza
umntu. Ukuba utata okanye umama unotshintsho okanye impazamo kwenye yezinto
eziphilayo ezenza i-Noonan syndrome, baya kuba nethuba elingama-50% lokuyidlulisela
kwindodana okanye intombi yabo, kumenze ukuba abe ne-Noonan syndrome.
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Kutheni sisenza esi sifundo?
Injongoyesisifundo kukufumanisa abantu abanothi babenamathuba okufumana i-Noonan
syndrome kwaye kwenziwe iimvavanyo zofuzo ukuze bachazwe impazamo yeDNA
ezibangele le meko kumntu. Ithemba kukuba oku kuya kusinceda ukuba siqinisekise ukuba
uchaphazelekile okanye awuchaphazelekanga, okunye kukunika uvavanyo olungcono
kwixesha elizayo kwezinye iintsapho ezichaphazelekayo yi-Noonan syndrome. Abaphandi
banethemba lokuqinisekisa ukuba alukho na olunye utshintsho kwimfuzo eyenza impawu
ezithile zemo okanye hayi.
Yintoni oya kundicela ukuba ndiyenze ukuba ndiyavuma ukuthathainxaxheba
kwesisifundo?
Ukuba uyavuma ukuba yinxalenye yesisifundo, uya kuvavanywa ngugqirha owenza
oluphando. Ukongezelela, uzotsalwa intwana yegazi.
Kuzokwenzekani kwi gazi lam nolwazi ngam?
Igazi lakho okanyeelomntwana wakho liya kujongisiswa ukubona utshintsho kwi-DNA
echaza isizathu sokuba babenesifo se-Noonan Syndrome. I-DNA iya kugcinelwa
ukuvavanywa kwe xesha elizayo. Le ngcaciso ingasetyenziselwa ukuvelisa iimpapasho
kodwa akukho lwazi oluchanekileyo ngawe elinothi lusetyenziswe.
Imfihlelo
Yonke inkcazelo enikeziweyo iyimfihlelo. Yonke ingcaciso nolwazi olubuthwe ngexesha
lesisifundo iya kugcinwa ngokukhuselekileyo kwiiofisi ezivaliweyo okanye kwiikhompyutha
ezikhuselweyo zegama. I-DNA iya kubhalwa ngendlela efihlakeleyo kwaye umntu osebenza
kweyakho akayi kukwazi ukuba ungubani. Umphandi akayi kubalisa ngenxaxheba yakho
koluphando kunye naziphi na izigulane okanye abantu abangabandakanyekanga kunyango
lwenu. Unokucelwa ukuba unike imvume yokupapasha iifoto ukuba ziye zathathwa
ngexesha loviwo lweklinikhi kodwa oku kuya kuba sisigqibo sakho.
Ziziphi iingozi zokubandakanyeka kwisifundo?
Umngcipheko wokulimala okanye ukungaxhamli okulindeleke kwesisifundo akwethusi. Xa
kuthathwa igazi ngenaliti kuyafana naxa utsalwa igazi kwezinye izigulo. Ungadumba
kancinci kodwa akafani kubeyinto exhalabisayo.
Ingaba zikhona naziphi na iinzuzokum?
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Umphandi angakuchazela unobangela wesisigulo kusapho lwakho.Ukuba kuthe
kwachaneka nto uzobizwa uchazelwe iziphumo. Oku kungakunikeza ulwazi olunoku nceda
wena nosapho lwakho. Ukuba kufumaniseke utshintsho kwi DNA yakho, usapho lonke
lungavavanywa ukuba lunomdla. Sicela usazise ukuba inombolo zakho zefowuni ziye
zatshintsha ngelixesha lesisifundo ukwenzela sikwazi ukukufumana xa kudingeka.
Kunyanzelekile ukuba ndithathe inxaxheba?
Hayi akunyanzelekanga, yonke lento iphuma kuwe. Ukuba uthe wafuna ukurhoxa sesiqhuba
esisifundo unalo ilungelo lokurhoxa kwaye lonto ayichaphazeli impilo yakho. Izigulane zonke
zizophathwa ngokulinganayo noba awuyo nxalenye yesisifundo. Ukhululkile ukuba ungacela
ingcebiso kwizihlobo nakusapho lwakho phambi kokuba uvume ukuba koluphando.
Ukhululekile ukuba ungafowunela ababantu bangezantsi ukuba uthe waba nemibuzo
okanye iingxaki ngoluphando:
Dr Cedrik Ngongang                                                 Prof Ambroise Wonkam
Tel: 021 406 6698                                                       Tel: 021 406 6307
E-mail: Cedrik.Ngongang@uct.ac.za E-mail: Ambroise.Wonkam@uct.ac.za
Sr Solomons
Tel: 021 406 6304
Ukubaunemibuzomayelananamalungeloakhonjengomntuothathainxaxhebakoluphandosicela
ufowunele u Prof M. Blockman,
usihlalowekomitiyezophandokwiUnivesithiyaseKapakulenombolo 021 406 6496
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Appendix 6: Xhosa version
UNIVESITHI YASE KAPA
CANDELO LWEZOFUZO LOLUNTU

































Sayina: ……………………………. Umhla: ……………………………
Umsayino wengqina: ............................................... Umhla: ...............................................




“Uphando lwezofuzo kuluntu lwase Mzantsi Afrika abaphila nesimo seNoonan Syndrome”
1. Oluphando lwenziwa ngogqirha base Univesithi yase Kapa ukuzama ukufunda
kabanzi ngesimo sezofuzo iNoonan Syndrome.
2. Wena namanye amalungu osapho lwakho nicelwe ukuba nibe yinxalenye yesisifundo
ngokuba esisifo singachaphazela usapho lwakho.













Appendix 8: Afrikaans version
UNIVERSITEIT VAN KAAPSTAD
DIVISIE VAN MENS GENETIKA
INFORMASIEBLAD VIR DEELNEMERS AAN NAVORSINGSTUDIE:
“Genetiese ondersoek van Suid-Afrikaners met die Noonan sindroom fenotipe, deurmiddel
van volgende generasie volgorde bepaling (Targeted Next Generation Sequencing)”
Geagte leser,
My naam is Cedrik Ngongang en ek is n mediese genetika dokter tans in opleiding by die
Universiteit van Kaapstad, Divisie van Mens Genetika.
U is genader om deel te neem aan hierdie studie omdat u of ‘n familielid, potensieel met
Noonan Sindroom gediagnoseer is.
Mense met Noonan sindroom het ‘n wye reeks van eienskappe, maar mees erkenbaar is ‘n
karakteristieke gesigs voorkoms en die geneigheid om korter as normaal te wees. Die
meeste volwassenes met Noonan sindroom is egter normale lengte. Sommige mense met
Noonan Sindroom mag ook ander problem hê soos hart- of leerprobleme. Ten spyte hiervan
sien ons dat die meeste mense met Noonan sindroom‘n relatiewe normale lewe lei. Vroeë
diagnose en gereelde mediese opvolg is belangrik om moontlike probleme te identifiseer.
Noonan sindroom is ‘n outosomaal dominante kondisie. Dit beteken dat seuns en dogters ‘n
gelyke kans het om geaffekteer te wees. Ons sien ook dikwels dat ‘n persoon wat met
Noonan sindroom gediagnoseer word, die eerste en enigste geaffekteerde persoon in die
spesifieke familie is. Sodra die sindroom egter in ‘n familie voorkom, kan dit oorgeërf word
en dus is daar families waar verskeie lede Noonan sindroom het. In een familie sien ons
egter wel ‘n spektum van simptome, dit beteken dat sekere lede ernstige simptome kan toon
terwyl ander geen simptome toon nie.
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Noonan sindroom word veroorsaak deur ‘n verandering in een van ons gene. DNA bestaan
uit gene wat die instruksies in ons liggame is om proteine te maak. Dit kan ook gesien word
as elke individue se spesifieke bouplan. Indien ‘n vader of moeder ‘n verandering (of fout)
dra in een van die gene wat Noonan sindroom veroorsaak, is daar dus met elke kind ‘n 50%
kans dat dit aan hulle oorgedra kan word. ‘n Kind met die oorgeërfde verandering sal dan
Noonan sindroom hê.
Waarom doen ons hierdie studie?
Die doel van hierdie studie is om individue wat ‘n moontlike diagnose van Noonan sindroom
het, te identifiseer en genetiese toetse op hulle te doen.  Sodoende kan ons moontlik die
genetiese fout identifiseer wat die kondisie veroorsaak het. Ons hoop dus om in die toekoms
mense meer akkuraat te kan diagnoseer en om beter toetse te kan bied vir families wat deur
Noonan sindroom geaffekteer word. Verdere navorsing rakende Noonan sindroom kan ook
moontlik navorsers in staat stel om te bepaal of daar enige spesifieke genetiese
veranderinge is wat spesifieke kenmerke van die Noonan sindroom veroorsaak.
Wat sal van my gevra word as ek instem om deel uit te maak van hierdie studie?
Indien u instem om deel te neem aan hierdie spesifieke studie, sal u ondersoek word deur
die dokter en ‘n bloed monster sal by u geneem word.
Wat sal gebeur met die informasie verkry uit die ondersoek van my bloedmonster?
U/u kind se bloed sal geanaliseer word om te kyk vir veranderinge in die DNA wat moontlik
kan verduidelik waarom u/u kind Noonan sindroom het. Die DNA sal gestoor word vir
moontlike toekomstige toetse. Hierdie informasie mag gebruik word vir publikasies, maar
geen identifiserende besonderhede sal bekend gemaak word nie.
Vertroulikheid
Alle informasie verskaf sal as vertroulik gesien word. Alle inligting wat deur hierdie studie
ingesamel word, sal veilig gestoor word in geslote kantore of in wagwoord-beskermde
rekenaars. Die DNA sal gekodeer word en die individu wat met die monster werk sal nie
weet aan wie dit behoort nie. Die navorser sal nie u deelname aan die studie bespreek met
enige ander pasiënte of persone wat nie by u mediese sorg betrokke is nie. Indien daar
foto’s geneem word tydens u kliniese ondersoek, mag u dalk gevra word om skriftelike
toestemming te verleen om die foto’s te publiseer. Dit sal egter u keuse wees of u
toestemming wil verleen of nie.
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Wat is die risiko’s van deelname aan hierdiestudie?
Die risiko vir skade of ongemak wat tydens hierdie studie verwag word, is nie groter as dit
wat u in die daaglikse lewe of gedurende ‘n roetine mediese ondersoek ervaar nie. Die naald
prik tydends die neem van u bloed dra dieselfde risiko’s as om bloed vir enige ander rede te
neem. Daar mag dalk kneusing wees, maar dit is gewoonlik nie ‘n ernstige probleem nie.
Is daar enige voordele vir my?
Die studie mag die oorsaak van Noonan sindroom in u familie identifiseer. Potensieel kan ‘n
diagnose van Noonan sindroom in u/u kind bevestig word. Indien ‘n oorsaak of variant
geïdentifiseer word, sal alle pogings gemaak word om u te kontak en die resultate in
persoon met u te bespreek. Informasie wat nuttig mag wees vir u/u kind en u familie sal
verskaf word. Indien ‘n verandering/fout geïdentifiseer word, mag die res van die familie
genetiese getoets word, as hulle sou belangstel en instem. Laat ons asseblief weet, indien u
kontak besonderhede sou verander gedurende hierdie studie periode, sodat ons u kan
bereik indien nodig.
Moet ek aan die navorsing deelneem?
Nee, dit is u eie keuse. U deelname aan hierdie studie is heeltemal vrywillig. Dit is ook
moontlik om enige tyd tydens die studie u deelname te beëindig en u mediese sorg sal nie
nadelig beinvloed word nie.  U sal dieselfde mediese behandeling ontvang of u instem om
deel te neem aan die studie of nie. Neem asseblief die vrymoedigheid om u familie en
naaste vriende se opinie te vra indien u onseker is oor deelname aan hierdie studie.
U kan enige een van die volgende mense kontak indien u enige probleme of verdere vrae
rakende die navorsing het:
Dr Cedrik Ngongang Prof Ambroise Wonkam
Tel: 021 406 6304                                     Tel: 021 406 6307
E-mail: Cedrik.Ngongang@uct.ac.za Email: Ambroise.Wonkam@uct.ac.za
Sr Solomons
Tel: 021 406 6304
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Indien u enige vrae rondom u regte as deelnemer aan hierdie navorsing studie het, kan u
Prof. M Blockman, hoof van die Navorsing Etiese Komitee (Research Ethics Committee) van
die Universiteit van Kaapstad kontak by 021 406 6496.
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Appendix 9: Afrikaans version
UNIVERSITEIT VAN KAAPSTAD
DIVISIE VAN MENS GENETIKA
INGELIGTE TOESTEMMING TOT NAVORSINGSPROJEK:
“Genetiese ondersoek van Suid-Afrikaners met die Noonan sindroom fenotipe, deurmiddel
van volgende generasie volgorde bepaling (Targeted Next Generation Sequencing)”
Ek, ………………………………………………………………………………………,gee hiermee
vrywilliglik toestemming dat my kind………………………………………………………... /my
genetiese material ondersoek mag word vir moontlike siekte-veroorsakende mutasies in die
gene wat Noonan sindroom in my familie veroorsaak.
INFORMASIE RAKENDE NAVORSINGSTUDIE :
Die doelstelling van hierdie studie is :
1. Om individue en families met Noonan sindroom te identifiseer
2. Om ‘n volledige kliniese ondersoek van elke geselekteerde pasiënt te doen
3. Om molekulêre analise op die genetiese monster van elke pasiënt te doen
4. Om die genotipe-fenotipe korrelasie van Noonan sindroom in die studie-populasie
vas te stel
Elke deelnemer sal:
1. ‘n Kliniese ondersoek deureen van die dokters by die Groote Schuur Hospitaal of
Rooikruis Kinderhospitaal ondergaan
2. Een buisie van 2-5ml bloed sal geneem word om DNA te verkry vir verdere
genetiese studies
Die DNA van die mense wat vermoedelik geaffekteer mag wees, sal slegs geanaliseer word
vir moontlike mutasies in gene wat Noonan sindroom veroorsaak. Indien enige mutasie
gevind word, mag familielede wat die risiko dra om dieselfde gene te hê in die toekoms
getoets word vir dieselfde mutasie. Deur in te stem tot hierdie studie, stem u ook in dat u
DNA geberg mag word vir toekomstige gebruik. Enige toekomstige genetiese ondersoeke
sal slegs verband hou met Noonan sindroom.
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Alle resultate sal, waar moontlik, gelewer word aan die relevante persone aan die einde van
die studieperiode. Implikasies vir hierdie resultate sal ook bespreek word as deel van die
genetiese raadgewings proses.
Deur in te stem tot hierdie navorsing studie word toestemming ook gegee vir die publikasie
van die resultate. Geen identifiserende besonderhede sal in die publikasie gebruikword nie,
maar foto’s mag wel gepubliseer word indien u toestemming daarvoor gegee het. Alle
informasie is konfidensieel.
Deelname aan hierdie studie is vrywillig en u mag op enige stadium onttrek sonder om enige
toekomstige sorg te benadeel.
Handtekening: ………………………………………… Datum: ……………………………
Getuiehandtekening: ………………………...………. Datum: ……………………………
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Appendix 10: Afrikaans version
UNIVERSITEIT VAN KAAPSTAD
DIVISIE VAN MENS GENETIKA
TOESTEMMING VIR NAVORSINGSPROJEK:
“Genetiese ondersoek van Suid-Afrikaners met die Noonan sindroom fenotipe, deurmiddel
van volgende generasie volgorde bepaling (Targeted Next Generation Sequencing)”
1. Hierdie studie word gedoen deur die dokters by die Universiteit van Kaapstad en
poog om meer te leer oor ‘n genetiese kondisie genaamd Noonan sindroom.
2. U en sekere van u familielede is gevra om deel te neem aan die studie aangesien
Noonan sindroom moontlik in u familie mag voorkom.
3. Die dokters probeer om meer te leer oor hoe iemand met Noonan sindroom lyk en
hoekom die kondisie gebeur. Hiermee poog hulle om u en ander mense se families
in die toekoms better te kan help.
4. Indien u besluit om deel van die studie te wees, sal een van die Genetika dokters u
ondersoek en een buisie bloed van 2-5ml neem.
5. Niks wat tydens die studie gedoen word sal u skade berokken nie.
6. Alle informasie wat gedurende die studie verkry word is vertroulik, dit beteken dat
niemand wat nie deel van die studie is nie, sal weet dat u deelgeneem het nie.
7. U kan self besluit of u deel van hierdie studie wil wees. Indien u besluit om nie deel te
neem nie sal niemand vir u kwaad wees nie en u sal steeds al die hulp en sorg
ontvangs wat u benodig.
Handtekening: ………………………………………… Datum: ……………………………
Getuiehandtekening: ………………………...………. Datum: ……………………………
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Appendix 11: Ethics Approval
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